Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/153746
Registo completo
Campo DCValorIdioma
dc.creatorMoreira-Rosário, A
dc.creatorMarques, C
dc.creatorPinheiro, H
dc.creatorAraújo, JR
dc.creatorRibeiro, P
dc.creatorRocha, R
dc.creatorMota, I
dc.creatorPestana, D
dc.creatorRibeiro, R
dc.creatorPereira, A
dc.creatorSousa, MJ
dc.creatorPereira-Leal, J
dc.creatorSousa, J
dc.creatorMorais, J
dc.creatorTeixeira, D
dc.creatorRocha, JC
dc.creatorSilvestre, M
dc.creatorPríncipe, N
dc.creatorGatta, N
dc.creatorAmado, J
dc.creatorSantos, L
dc.creatorMaltez, F
dc.creatorBoquinhas, A
dc.creatorSousa, G
dc.creatorGermano, N
dc.creatorSarmento, G
dc.creatorGranja, C
dc.creatorPóvoa, P
dc.creatorFaria, A
dc.creatorCalhau, C
dc.date.accessioned2023-11-08T09:57:40Z-
dc.date.available2023-11-08T09:57:40Z-
dc.date.issued2021
dc.identifier.issn1664-302X
dc.identifier.urihttps://hdl.handle.net/10216/153746-
dc.description.abstractThe risk factors for coronavirus disease 2019 (COVID-19) severity are still poorly understood. Considering the pivotal role of the gut microbiota on host immune and inflammatory functions, we investigated the association between changes in the gut microbiota composition and the clinical severity of COVID-19. We conducted a multicenter cross-sectional study prospectively enrolling 115 COVID-19 patients categorized according to: (1) the WHO Clinical Progression Scale—mild, 19 (16.5%); moderate, 37 (32.2%); or severe, 59 (51.3%), and (2) the location of recovery from COVID-19—ambulatory, 14 (household isolation, 12.2%); hospitalized in ward, 40 (34.8%); or hospitalized in the intensive care unit, 61 (53.0%). Gut microbiota analysis was performed through 16S rRNA gene sequencing, and the data obtained were further related to the clinical parameters of COVID-19 patients. The risk factors for COVID-19 severity were identified by univariate and multivariable logistic regression models. In comparison to mild COVID-19 patients, the gut microbiota of moderate and severe patients have: (a) lower Firmicutes/Bacteroidetes ratio; (b) higher abundance of Proteobacteria; and (c) lower abundance of beneficial butyrate-producing bacteria such as the genera Roseburia and Lachnospira. Multivariable regression analysis showed that the Shannon diversity index [odds ratio (OR) = 2.85, 95% CI = 1.09–7.41, p = 0.032) and C-reactive protein (OR = 3.45, 95% CI = 1.33–8.91, p = 0.011) are risk factors for severe COVID-19 (a score of 6 or higher in the WHO Clinical Progression Scale). In conclusion, our results demonstrated that hospitalized patients with moderate and severe COVID-19 have microbial signatures of gut dysbiosis; for the first time, the gut microbiota diversity is pointed out as a prognostic biomarker of COVID-19 severity.
dc.description.sponsorshipThis study was sponsored by the Fundação para a Ciência e a Tecnologia (FCT, project no. 268_596883842), BIOCODEX, and CINTESIS (reference UIDB/4255/2020). The funders had no role in study design, data collection, data analysis, data interpretation, or manuscript writing.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofFrontiers in Microbiology, vol.12:705020
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectDysbiosis
dc.subjectGut microbiota
dc.subjectShannon—Weiner diversity index
dc.subjectWHO Clinical Progression Scale
dc.titleGut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3389/fmicb.2021.705020
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fmicb.2021.705020/full
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3389-fmicb.2021.705020.pdf558.51 kBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons